These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 29986966)

  • 21. Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison.
    Alexopoulos D; Kontoprias K; Gkizas V; Karanikas S; Ziakas A; Barampoutis N; Tsigkas G; Koutsogiannis N; Davlouros P; Patsilinakos S; Karvounis H; Hahalis G; Xanthopoulou I
    Platelets; 2016 Jul; 27(5):420-6. PubMed ID: 26763727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention.
    Choi KN; Jin HY; Shin HC; Park YA; Seo JS; Jang JS; Yang TH; Kim DK; Kim DS
    Am J Cardiol; 2017 Jul; 120(2):201-206. PubMed ID: 28554486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H²⁴ Analysis.
    Montalescot G; van 't Hof AW; Bolognese L; Cantor WJ; Cequier A; Chettibi M; Collet JP; Goodman SG; Hammett CJ; Huber K; Janzon M; Lapostolle F; Lassen JF; Licour M; Merkely B; Salhi N; Silvain J; Storey RF; Ten Berg JM; Tsatsaris A; Zeymer U; Vicaut E; Hamm CW;
    JACC Cardiovasc Interv; 2016 Apr; 9(7):646-56. PubMed ID: 26952907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
    Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
    Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
    Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study.
    Kubica J; Adamski P; Buszko K; Kubica A; Kuliczkowski W; Fabiszak T; Jilma B; Alexopoulos D; Paciorek P; Navarese EP
    Eur Heart J Cardiovasc Pharmacother; 2018 Jul; 4(3):152-157. PubMed ID: 29040445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome.
    Caiazzo G; De Rosa S; Torella D; Spaccarotella C; Mongiardo A; Giampà S; Micieli M; Palella E; Gulletta E; Indolfi C
    Circ Cardiovasc Interv; 2014 Feb; 7(1):104-12. PubMed ID: 24449597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS).
    Musallam A; Orvin K; Perl L; Mosseri M; Arbel Y; Roguin A; Lev EI
    Can J Cardiol; 2016 Oct; 32(10):1246.e13-1246.e19. PubMed ID: 26971236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.
    Dong P; Yang X; Bian S
    Med Sci Monit; 2016 Dec; 22():4929-4936. PubMed ID: 27977637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation.
    Verdoia M; Sartori C; Pergolini P; Nardin M; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Vascul Pharmacol; 2016 Feb; 77():48-53. PubMed ID: 25956733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
    Bernlochner I; Mayer K; Orban M; Morath T; Jaitner J; Rössner L; Gross L; Laugwitz KL; Kastrati A; Sibbing D
    Platelets; 2016 Dec; 27(8):796-804. PubMed ID: 27275651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention.
    Bonello L; Laine M; Thuny F; Paganelli F; Lemesle G; Roch A; Kerbaul F; Dignat-George F; Berbis J; Frere C
    Int J Cardiol; 2016 Aug; 216():190-3. PubMed ID: 27179310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events.
    Alexopoulos D; Stavrou K; Koniari I; Gkizas V; Perperis A; Kontoprias K; Vogiatzi C; Bampouri T; Xanthopoulou I
    Thromb Haemost; 2014 Sep; 112(3):551-7. PubMed ID: 24990396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose.
    Holm M; Tornvall P; Westerberg J; Rihan Hye S; van der Linden J
    Platelets; 2017 Nov; 28(7):706-711. PubMed ID: 28150519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Ticagrelor on Coronary Blood Flow and Prognosis in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention in Real World.
    Jin YY; Bai R; Ai H; Nie SP
    Chin Med J (Engl); 2018 Nov; 131(21):2634-2636. PubMed ID: 30381606
    [No Abstract]   [Full Text] [Related]  

  • 36. Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor.
    Barbieri L; Verdoia M; Pergolini P; Nardin M; Rolla R; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):352-8. PubMed ID: 26857781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretreatment with ticagrelor may offset additional inhibition of platelet and coagulation activation with bivalirudin compared to heparin during primary percutaneous coronary intervention.
    Venetsanos D; Lindahl TL; Lawesson SS; Gustafsson KM; Wallen H; Erlinge D; Swahn E; Alfredsson J
    Thromb Res; 2018 Nov; 171():38-44. PubMed ID: 30248659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS).
    Bergmeijer TO; Godschalk TC; Janssen PWA; Berge KVD; Breet NJ; Kelder JC; Hackeng CM; Ten Berg JM
    Semin Thromb Hemost; 2017 Jun; 43(4):439-446. PubMed ID: 28561235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Barbieri L; Pergolini P; Verdoia M; Rolla R; Nardin M; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Vascul Pharmacol; 2016 Apr; 79():11-15. PubMed ID: 26518440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
    Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.